Solid start to the year: 13% revenue growth driven by strong performance in dermatology3.5.2024 09:00:00 CEST | LEO Pharma

Q1 2024 Trading Update (Unaudited): In Q1 2024, LEO Pharma delivered a revenue growth of 13% in constant exchange rates (CER). The dermatology portfolio saw accelerated growth in revenue of 16%. The acquisition of TMB-001 to the treatment of congenital ichthyosis added a late-stage asset to LEO Pharma’s medical dermatology pipeline, and delgocitinib for chronic hand eczema (CHE) is on track for its planned European launch in Q4 2024. Full-year outlook has been revised slightly upwards.
  • 1
  • 2
  • 3
  • 4
  • 5
  • Sidste
  • >>
HiddenA line styled icon from Orion Icon Library.Eye